{"filing":{"accession_number":"0001171843-26-004516","cik":"0001581178","ticker":"EPRX","company_name":"EUPRAXIA PHARMACEUTICALS INC.","form":"6-K","filing_date":"2026-07-07","report_date":null,"primary_document":"f6k_070726.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1581178/000117184326004516/f6k_070726.htm"},"events":[{"id":16443,"run_id":14696,"accession_number":"0001171843-26-004516","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The press release announces the appointment of three industry leaders—Robert Bazemore, Amy Pott, and Dr. Helen Thackray—to Eupraxia's Board of Directors. Each appointee brings substantial experience in drug development, commercialization, and clinical leadership. The CEO explicitly states their expertise will be \"invaluable as we execute on several key upcoming milestones,\" indicating material governance strengthening at a pivotal stage for the company.","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-07-07","form":"6-K","submitted_at":null,"items":[{"id":14540,"accession_number":"0001171843-26-004516","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of three industry leaders—Robert Bazemore, Amy Pott, and Dr. Helen Thackray—to Eupraxia's Board of Directors. Each appointee brings substantial experience in drug development, commercialization, and clinical leadership. The CEO explicitly states their expertise will be \"invaluable as we execute on several key upcoming milestones,\" indicating material governance strengthening at a pivotal stage for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:21:41.528326+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14540,"accession_number":"0001171843-26-004516","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The press release announces the appointment of three industry leaders—Robert Bazemore, Amy Pott, and Dr. Helen Thackray—to Eupraxia's Board of Directors. Each appointee brings substantial experience in drug development, commercialization, and clinical leadership. The CEO explicitly states their expertise will be \"invaluable as we execute on several key upcoming milestones,\" indicating material governance strengthening at a pivotal stage for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-07T20:21:41.528326+00:00","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-07-07"}]}